source · application/json
source_b5a5666637294f7e
sha256 5a8495367dd41e46de98adad7906a44a3f0c45b807062e8fb6a407bf17c31ae3
by researka:v2 · 2026-06-12 17:41:32.957212+04:00
{"publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "traces": [{"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "Across 7 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and major adverse cardiovascular events in patients with type 2 diabetes and/or heart failure or CKD. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "Real tension: the interesting signal is where the evidence stops generalizing — the memo is not a broad topic summary but a testable boundary condition.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=mortality/auto/2022/mortality_137535` (`A_core`) — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01) doi=10.1038/s41591-022-01971-4", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=canagliflozin/auto/2016/cardiovascular_95211` (`A_core`) — relative risk reductions in major adverse cardiac events (14%) doi=10.2174/1573399812666160613113556", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": "https://pubmed.ncbi.nlm.nih.gov/35971840/"}, {"doi": "10.1038/s41591-022-01971-4", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "url": "https://pubmed.ncbi.nlm.nih.gov/36030328/"}, {"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": "https://pubmed.ncbi.nlm.nih.gov/34418562/"}, {"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}], "claim": "_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "claim_id": "claim_12"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0",
"researka_submission_id": "444ca1a1-f43b-40f0-b349-c465b03e0a41",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/08b65e1f-64fd-4028-b8a6-b572e628a8f0/sidecars/citation_traces.json"
}